Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease : A multicenter observational case-control study

Sekizaki, Tomonori; Kameda, Hiraku; Nomoto, Hiroshi et al.

Journal of diabetes investigation, 2021, 12(11), 1978-1982

Permalink : https://hdl.handle.net/2115/82226

このアイテムのアクセス数:607件（2026-10-15 11:51 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1111/jdi.13578     93

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/82226
タイトル
Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease : A multicenter observational case-control study
著者
Sekizaki, Tomonori ; Kameda, Hiraku ; Nomoto, Hiroshi ; Cho, Kyu Yong ; Nakamura, Akinobu ; Takahashi, Kiyohiko ; Miyoshi, Arina ; Wada, Norio ; Takeuchi, Jun ; Nagai, So ; Miyoshi, Hideaki ; Atsumi, Tatsuya
著者名
Sekizaki, Tomonori
e-Rad_Researcher
20826127
著者名
Kameda, Hiraku
著者名
Nomoto, Hiroshi
著者名
Cho, Kyu Yong
著者名
Nakamura, Akinobu
著者名
Takahashi, Kiyohiko
著者名
Miyoshi, Arina
著者名
Wada, Norio
著者名
Takeuchi, Jun
著者名
Nagai, So
著者名
Miyoshi, Hideaki
著者名
Atsumi, Tatsuya
言語
英語
キーワード
Dipeptidyl peptidase-4
Graves' disease
Case-control study
発行日
2021-07-15
出版者
John Wiley & Sons
収録物名
Journal of diabetes investigation
巻(号)
12(11)
ページ
1978-1982
抄録
Dipeptidyl peptidase-4 (DPP-4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP-4 might affect the immune system. The current multicenter observational case-control study was carried out to investigate the effects of DPP-4 inhibitor (DPP-4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP-4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non-exacerbation group. The frequency of DPP-4i administration was significantly higher in the exacerbation group (88%) than that in the non-exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP-4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP-4i administration is associated with GD exacerbation.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
2040-1116
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1111/jdi.13578